More validation is emerging for the furin protease (“furin”) hypothesis I posited in this blog: The Furin Protease Connection: From SARS CoV-2 and Anthrax, to Diabetes and Hypertension and that is now available as a pre-print publication here. Considering furin protease inhibitors Scientists are validating furin inhibition as a possible pathway to addressing COVID. And in this Medical News Today…
ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS coronavirus 2, or SARS-CoV-2) is the cause of the respiratory infection known as COVID-19. From an immunopathological standpoint, coronaviruses such as SARS-CoV-2 induce increased levels of a variety of T-helper 1 (Th1) and inflammatory cytokines and chemokines, including interleukin-1 (IL-1), IL-6, CCL2 protein, and CXCL10 protein. In…
A new Harvard-led analysis finds that COVID-19 patients that live in areas with higher air pollution, such as New York City, have experienced a higher death-rate from the infection than those who lived in areas with cleaner air.
The cytokine storm seen in SARS Cov1 and Cov2 might be due to chronic pyroptosis activation. However, known activators of NLRP3 in SARS-CoV differ from CoV2. While SARS Cov1 and COVID19 are genetically very similar, the extraordinarily high rate of infectivity of COVID19 is unique. Prepublication research suggests the cause might be a unique furin-like cleavage site on the spike protein of Cov2 that was absent in Cov1.
Today, my goal is to bang out what *I think* may be critical botanical and nutraceutical interventions for COVID19 (SARS Cov2) prevention and treatment.
